Monocyte subtypes predict clinical course and prognosis in human stroke

Abstract

The number of circulating monocytes increases after stroke. In this study, we assessed the time course and phenotype of monocyte subsets and their relationship with the clinical course and outcome in 46 consecutive stroke patients and 13 age-matched controls. The proportion of the most abundant classical CD14highCD16 monocytes did not change after stroke, whereas that of CD14highCD16 monocytes increased and CD14dimCD16 monocytes decreased. CD14highCD16 monocytes had the highest expression of TLR2, HLA-DR and the angiogenic marker, Tie-2; CD14 dimCD16 monocytes had the highest expression of costimulatory CD86 and adhesion molecule CD49d. Platelet monocyte interactions were highest in CD14highCD16 monocytes and lowest in CD14dimCD16 monocytes. In adjusted models, 1 CD14highCD16 monocytes were associated with poor outcome (OR: 1.38), higher mortality (OR: 1.40) and early clinical worsening (OR: 1.29); 2 CD14highCD16 monocytes were inversely related to mortality (OR: 0.32); and 3 CD14dimCD16 monocytes were inversely related to poor outcome (OR: 0.74) and infarction size (r0.45; P0.02). These results illustrate that the predominant monocyte subtype conveys harmful effects after stroke, which include stronger interaction with platelets. Alternatively, rarer subpopulations of monocytes are beneficial with a phenotype that could promote tissue repair and angiogenesis. Therefore, monitoring of monocyte subtypes may emerge as a useful tool at the bedside for stroke patients.© 2009 ISCBFM All rights reserved.